It has been observed that trauma patients often display elevated procoagulant activity that could be caused, in part, by tissue factor (TF). We previously observed that trauma patients with thermal, blunt, and penetrating injuries have active FIXa and FXIa in their plasma. In the current study, we evaluated the effect of injury severity, with or without accompanying shock, on the frequency and concentration of TF, FIXa, and FXIa in plasma from trauma patients.
T rauma is the leading cause of death worldwide among young adults, 1 in which uncontrolled hemorrhage accounts for approximately 60% of deaths in patients whose injuries were potentially treatable. 2 Survival of the patient depends on the management of two conditions: early-phase bleeding and latephase thrombosis. 3 The protocol for early-phase bleeding involves massive transfusions and, as more information comes to light regarding trauma-induced coagulopathy (TIC), more alterations are being made in the management of bleeding after severe trauma. 4 Early detection of coagulopathy is critical as it is indicative of injury severity and is a prognostic factor for transfusions. 5 A multitude of factors contribute to TIC, including anemia, hemodilution, hypothermia, acidosis [defined as shock in terms of base deficit (BD)], hemorrhagic shock, and the trauma itself. 3 On the other hand, severe acidosis (pH ≤7.1) has been shown to inhibit the propagation phase of thrombin generation and accelerate fibrin degradation, 6 thus contributing to overall hemostatic changes in trauma patients.
The elevated procoagulant activity of trauma patients has been hypothesized to be caused, in part, by tissue factor (TF) located on the subendothelium, blood cells, 7 microparticles, 8 and more recently suggested on platelets, 9 although this last claim is disputed. 10, 11 TF is a membrane-bound glycoprotein that initiates coagulation when exposed to FVIIa circulating in blood, subsequently forming the extrinsic factor (F)Xase (FVIIa:TF) complex, which activates FIX and FX and ultimately results in thrombin generation. Robust thrombin generation leads to cleavage of fibrinogen and activation of FXIII, allowing the formation of a solid fibrin clot. 12 Elevated levels of TF antigen have been observed in a multitude of illnesses associated with tissue damage 13, 14 and hematologic disorders. 15, 16 In addition to TF, we have previously observed detectable and active FXIa and FIXa corresponding to a worse prognosis in the plasma of cardiovascular 13, 16, 17 and trauma patients, often present for several days to weeks. 18, 19 Although TF initiates the extrinsic pathway of coagulation, FXI(a) plays a role in both the intrinsic (contact) and extrinsic pathways and is directly upstream of FIX. FXIa subsequently activates FIX to FIXa, which complexes with FVIIIa and leads to FX activation-the so-called merging point of the two pathways. FXI can be activated via the contact pathway by FXIIa on artificial surfaces or under more physiologic conditions in a feedback loop by thrombin via the extrinsic pathway. 12 DNA and RNA released from stimulated and dying cells 20, 21 along with polyphosphates released from activated platelets 22, 23 have also been shown to lead to FXIa generation by FXIIa. Elevated levels of FXIa have been detected and implicated in a number of prothrombotic states, 13, 17, 24 and deficiencies have been shown to protect against ischemic stroke.
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Our previous studies showed that the only three proteins endogenously present in trauma patient plasma capable of initiating thrombin generation, and consequentially coagulation, are active TF, FXIa, and FIXa. 18, 19 It is not known how the release of TF, FXIa, and FIXa is affected by injury type and severity; therefore, in our current study, we examined plasma from trauma patients with the hypothesis that the severity of an injury with or without accompanying shock would correlate with higher frequencies and concentrations of these three proteins.
METHODS

Materials
Pooled citrate platelet-poor plasma was prepared in-house using 10 healthy donors. 13 Trypsin inhibitor from corn (CTI; prevents contact pathway initiation of coagulation) was prepared as previously described. 26, 27 Phospholipid vesicles (PCPS) composed of 25% dioleoyl-sn-glycero-3-phospho-L-serine and 75% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (both from Avanti Polar Lipids, Inc., Alabaster, AL) were prepared as previously described. 28 Inhibitory monoclonal anti-TF (αTF-5; prevents binding of TF to FVIIa), anti-FXIa (αFXI-2; inhibits FIX activation by FXIa), and anti-FIXa (αFIX-91; inhibits FX activation by FIXa) antibodies were produced and characterized in-house. 29, 30 The fluorogenic substrate used was benzyloxycarbonyl-Gly-GlyArg-7-amido-4-methylcoumarin•HCl (Z-GGR-AMC) (Bachem, Torrance, CA). TF, FIXa, and FXIa activity in plasma was calculated from calibration curves developed with human FIXa, human FXIa, and relipidated TF 26 (all from Haematologic Technologies, Inc., Essex Junction, VT). Human thrombin was produced in-house. 31 HBS buffer was prepared using N-[2-hydroxyethyl] piperazine-NN-[2-ethanesulfonic acid] (HEPES) and NaCl (Fisher Scientific, Waltham, MA) (HBS; 20 mM HEPES, 0.15 M NaCl, pH 7.4). CaCl 2 used was from Fisher Scientific (Waltham, MA). The thrombin generation assay was performed in untreated, polystyrene 96-well plates (Costar, Lowell, MA). The plate reader used was the BioTek Synergy 4 and analysis was performed using the Gen5 plate reader software (BioTek, Winooski, VT).
Patients
Eighty trauma patients from a major urban Level I trauma center were selected based on presence or absence of severe injury [Injury Severity Score (ISS) > 15] and presence or absence of shock (BD ≤−6 mmol/L) ( 
Blood Sample Collection and Citrate Plasma Preparation
The study was approved by the University of California, San Francisco Committee on Human Research. The mechanism of consent consisted of an initial waiver of informed consent allowing blood draws before getting patient or surrogate consent. As soon as possible, full written informed consent was obtained from the patient or family (depending on condition). If surrogate consent was obtained and the patient status improved, then a follow-up for patient written consent occurred. The consent mechanism also consisted of waivers of consent that had the approval to be applied in appropriate circumstances, such as the patient's expiration, the patient's inability to regain capacity for consent (followed for at least 30 days), the absence of family, etc. If unable to obtain consent and the appropriate waiver could not be applied, the patient was excluded from the study and the collected blood sample(s) were discarded. All patients in this study were either consented (written, by family and/or by patient) into the study or had an IRB-approved waiver applied.
Blood samples were collected at each patient's initial 0 hour draw and citrate plasma was prepared, frozen, and stored at −80°C. No additional freeze/thaw cycles were involved before FXIa, FIXa, and TF activity assays.
Thrombin Generation Assay (TGA) for FXIa, FIXa, and TF
The assay is a modification of previously published assays 32, 33 and is based on the response of the lag phase of thrombin generation in contact-pathway-inhibited (CTI) plasma to the addition of inhibitory monoclonal antibodies to FXIa, FIXa, and TF. Citrated plasma samples were thawed at 37°C for 3 minutes and 5 mg/mL CTI was immediately added to achieve a 0.1 mg/mL final concentration. Eighty microliters of each plasma sample was added to a 96-well plate and inhibitory monoclonal antibodies (anti-TF, anti-XI, and anti-IX) were added (when desired) to achieve a 0.1 mg/mL final concentration. Twenty microliters of a 2.5 mM Z-GGR-AMC/90 mM CaCl 2 solution in HBS was added to plasma samples to achieve final concentrations of 417 μM/15 mM, respectively, followed by a 3-minute incubation period at 37°C to allow recalcification of the plasma. Twenty microliters of a 120 μM PCPS solution in HBS was then added to plasma samples to achieve a final concentration of 20 μM, thus initiating thrombin generation. Fluorescence readings began immediately and hydrolysis of the AMC substrate (at 370 nm excitation and 460 nm emission wavelengths) was followed over a 3,600-second period. Changes in fluorescence were converted to thrombin concentration using a calibration curve built by sequential dilutions of human thrombin. Concentrations of TF, FXIa, and FIXa were calculated from corresponding calibration curves constructed by titrating purified proteins into multidonor pooled plasma from healthy individuals.
Quantitation of Endogenous FXIa, FIXa, and TF Activity in TGA
In the absence of an exogenous initiator, recalcified citrate plasma containing CTI from healthy individuals (multi-donor or individual donors) does not generate any detectable level of thrombin during the 60-minute duration of the assay. In contrast, the majority of trauma patients with a wide range of both injury type and severity do generate relatively high levels of thrombin under the same experimental conditions. This relatively robust thrombin generation is exemplified in Figure 1 as it shows thrombin production over time in a trauma patient plasma sample without the addition of an exogenous initiator yielding a lag phase of 514 seconds, a peak thrombin value of 441 nM, and a maximum rate of generation of 7.1 nM/s. To compare, healthy plasma initiated with 5 pM relipidated TF yields a lag phase of 501 seconds, a peak thrombin value of 83 nM, and a maximum rate of generation of 1.6 nM/s.
To quantitate endogenous concentrations of the three proteins in a given plasma sample, inhibitory monoclonal antibodies against each protein were individually added to separate sample aliquots and the prolongation in the lag phase was determined. Previously performed titrations of TF, FXIa, and FIXa into multi-donor plasma under the same experimental conditions showed a linear response of the lag phase to the amount of exogenous protein added. Based on such calibration curves, the prolongation in the lag phase from the endogenous potential to that when αTF is added ( Fig. 1) (from 514 to 696 seconds) corresponds to a TF concentration of 2.7 pM. Had the addition of αTF led to virtually no difference in thrombin generation profiles, it would be concluded that the plasma sample contained no active TF. A similar quantitation was done to obtain FXIa levels by measuring the prolongation of the lag phase with the addition of an αFXI antibody. In Figure 1 , the prolongation from 514 seconds to 1,424 seconds corresponds to a FXIa concentration of 33.8 pM. Furthermore, a prolongation of the lag phase from 1,424 seconds to >3,600 seconds, i.e., the complete abolishment of thrombin generation over the duration of the assay, with the addition of an αFIX antibody corresponds to a FIXa concentration of 155 pM.
Statistical Analysis
Comparison of TF, FXIa, and FIXa frequency on the basis of injury severity or shock was conducted using Fisher's exact test with 95% confidence intervals and corresponding p values, with a statistical significance limit of p < 0.0025 to control for pairwise comparisons within each group. For analysis of injury severity, groups 1 and 2 were combined (non-severe injury) and groups 3 and 4 were combined (severe injury). Similarly, for the analysis of shock, groups 1 and 3 were combined (no shock) and also groups 2 and 4 (with shock).
RESULTS
Patients
Across all four groups, the ISS varied between 1 and 75 (average 19.3 ± 17.2). For group 1, there was 10% mortality at discharge, a median of 3.5 days spent in the hospital, and a range of ISS scores from 1 to 14 with two patients (10%) sustaining TBI. Group 2 had a similar percent mortality at discharge and median hospital stay (10% and 2.5 days, respectively) along with a range of ISS scores from 1 to 13 with no patients sustaining TBI. Unlike groups 1 and 2, group 3 had both a greater percent mortality and median hospital stay (45% and 14 days, respectively) along with a wider range of ISS scores and percent TBI (17-59 and 75%, respectively). Similarly, group 4 had a 45% mortality at discharge, a median stay of 8 days in the hospital, and a range of ISS scores from 16 to 75 with 60% of patients sustaining TBI. According to available data, one patient from group 2 received 4 units of packed red blood cells (pRBC) and 1 L plasmalyte before their draw along with three patients from group 4 who each received 1 unit of pRBC before their draws. All patients who received blood product transfusions fell within the range of TF, FXIa, and FIXa levels in their respective groups.
Tissue Factor
TF activity was observed in 33 of 80 patient samples (41.3%) ( Table 2 ). The frequency of TF in patients with nonsevere injuries from groups 1 and 2 was relatively low (20% and 15%, respectively) and increased by at least threefold in patients with severe injury from groups 3 and 4 (60% and 70%, respectively). Groups were combined on the basis of severe versus non-severe injury and the relative risk (RR) for the presence of TF was calculated to be 3.71 [95% confidence interval (CI) = 1.83-7.56], indicating that individuals with severe injuries are upwards of four times more likely to have detectable levels of TF in this thrombin generation assay than individuals with non-severe injuries. When groups were combined based on the presence or absence of shock (groups 2 and 4 and groups 1 and 3, respectively), the RR calculated was approximately 1 (RR = 1.06; 95% CI = 0.63-1.79), indicating no correlation between detectable TF and the presence of shock.
The concentration of TF varied in a wide range in all four groups, but was the lowest in samples from patients with nonsevere injuries (groups 1 and 2, both with median values of 0 pM) and the highest in those from patients with severe injuries (groups 3 and 4 with median values of 0.4 pM and 0.6 pM, respectively). The entire range of TF concentrations across all four groups (0 pM to >6.4 pM) was divided into five sub-ranges and the prevalence in each was established for each group (Fig. 2, A) , again illustrating that most often the highest concentrations of TF are found in patients with severe injury from groups 3 and 4.
Factor XIa
Overall, FXIa was observed in 73 out of 80 patient samples (91%) and the frequency was similar across all four groups of patients, regardless of injury severity and/or shock (90%, 95%, 85%, and 95% for groups 1, 2, 3, and 4, respectively). It was calculated that individuals with severe injury were just as likely to have detectable levels of FXIa as individuals with non-severe injuries (RR = 0.97; 95% CI = 0.85-1.12) and, additionally, the presence of shock was shown to have just as much of an effect on FXIa frequency as the absence of shock (RR = 1.09; 95% CI = 0.95-1.25).
Similar to TF, the concentration of FXIa varied in a wide range in the entire study population (0 pM to >64 pM). Unlike TF, however, FXIa was present at higher concentrations in patients with shock from groups 2 and 4 (median values of 23.2 pM and 25.2 pM, respectively) and did not correlate with the severity of Figure 2 . Distribution of TF (A), FXIa (B), and FIXa (C) concentrations in trauma patient groups (see Table 1 ).
injury in patients from groups 1 and 3 (median values of 5.7 pM and 6.8 pM, respectively). As with TF, the entire range of FXIa concentrations across all four groups was divided into five subranges and the prevalence in each was established for each group (Fig. 2, B) . As expected, high FXIa concentrations were observed at a higher frequency in groups 2 and 4 (with shock) than in groups 1 and 3 (without shock).
Factor IXa
Active FIXa was observed in 64 out of 80 patients (80%). From group 1 plasma samples, only 9 out of 20 (45%) had detectable FIXa, whereas in groups 2 to 4, only 1 or 2 plasma samples had no FIXa activity (90-95% frequency). It was calculated that individuals with severe injury are slightly more likely to have detectable levels of FIXa than individuals with non-severe injury (RR = 1.37; 95% CI = 1.09-1.73), along with the presence of shock versus no shock (RR = 1.37; 95% CI = 1.09-1.73).
As with TF and FXIa, there was a very wide range of FIXa concentrations across all four groups (0 pM to >1,000 pM) and also within all groups (Table 2) . Unlike TF and FXIa, the median concentration of FIXa varied in a relatively narrow range between groups 2, 3, and 4 (250 pM, 197.5 pM, and 197.5 pM, respectively), and the lowest was observed in group 1 (0 pM). The range of concentrations was divided into five sub-ranges and the prevalence was established in each group (Fig. 2, C) , illustrating the lack of correlation between FIXa levels and injury severity (groups 3 and 4) and/or presence of shock (groups 2 and 4).
For patients with quantifiable amounts of the three proteins within the entire cohort, there was a good correlation between FIXa and FXIa concentrations (R 2 = 0.36; Fig. 3 ), but no correlation between TF and FXIa or FIXa was observed (data not shown).
DISCUSSION
In this study, we illustrate the prevalence and wide range of TF, FXIa, and FIXa concentrations in plasma from trauma patients with various ISS and BD scores that correspond to the extent of injury and level of shock, respectively. The levels and frequencies of these three proteins are shown to correlate with either trauma severity or shock or both.
TF, an integral membrane protein found in many types of cells, is an important and highly studied initiator of the blood coagulation process. Multiple studies have shown the expression of TF activity on blood cells such as monocytes and neutrophils upon stimulation with agonists such as inflammation-related cytokines 7 and also on microparticles 8 shed from such blood cells. More recently, the presence of TF in platelet α granules has been suggested, 9 although there is no common agreement with regard to the presence of TF activity and antigen in platelets. 10, 11 In whole blood from healthy individuals, levels of active TF do not exceed 20 fM, if at all present, 7, 34 whereas increased levels of TF antigen have been previously observed in patients suffering from a multitude of illnesses associated with tissue damage that are independent of shock, including cardiovascular diseases, 13 trauma, and subsequent sepsis. 14 Along with those disorders associated with tissue damage, increased TF levels have been detected in hematologic disorders such as sickle-cell disease 15 and cerebrovascular events. 16 Although there is debate as to the origin and prevalence of TF in the blood of both healthy and non-healthy individuals, our data regarding TF being of the highest frequencies and concentrations in the cohorts with the highest trauma severity is consistent with the knowledge that TF, located on the subendothelium of all blood vessels larger than capillaries, 35 is positioned in such a way as to trigger the coagulation cascade after prominent vessel damage and subsequent intravascular exposure. 36 This is also consistent with studies that have shown that TF activity becomes enhanced by endotoxin stimulation and inflammation, 7 which may occur after the tissue disruption during severe trauma. Because shock, in terms of BD, does not directly reflect tissue damage but more so metabolic alterations, it is perhaps somewhat expected that BD had less effect on TF presence/activity in trauma patients than injury severity.
As TF plays a critical role in the initiation of the extrinsic pathway of coagulation, FXI(a) maintains a role in both the intrinsic (contact) and extrinsic pathway and can be activated via either route. In TF-triggered hemostasis, FXIa is generated in a feedback loop by thrombin, thus bypassing the contact pathway; 12 however, under certain conditions, FXIa can be generated via activation by FXIIa. Such conditions include exposure of blood to artificial surfaces (classically stated as negatively charged surfaces but also occurring on neutral or positively charged surfaces), 37 polyphosphate release from stimulated or dying cells (DNA and RNA), 20, 21 and inorganic polyphosphate release from activated platelets. 22, 23 Activated FXI subsequently activates FIX, which, in complex with FVIIIa, activates FX to FXa and ultimately leads to thrombin generation. FXIa can also enhance thrombin generation by activating FV and FVIII 38 and by proteolysis of tissue factor pathway inhibitor. 39 Increased levels of FXIa have been shown to correlate with a higher risk of venous thrombosis, 40 and, on the other end of the spectrum, FXI deficiencies have been shown to protect against ischemic stroke. 25 There is mounting evidence that illustrates the importance of the intrinsic pathway in thrombosis 41 and suggests contact pathway proteins such as FXII and FXI as prime targets for antithrombotic strategies. 42 Increased thrombotic risk known to confer with high plasma concentrations of FXI may be explained by an increase in endogenous thrombin potential 43 and/or impaired fibrinolysis and increased clot stability, thus lessening the elimination of thrombi within blood vessels. Although FXIa is not observed in the plasma of healthy individuals, 13 it has been detected and implicated in prothrombotic states observed in acute coronary syndrome 13 and stable angina 17 along with hypertensive individuals 45 and those with chronic obstructive pulmonary disease. 46 The presence of FXIa in patients with ischemic cerebrovascular events has been shown to correspond with worse prognosis, 47 which could suggest the use of FXIa as a novel thrombotic marker for worse outcome in such a population. Active FXIa is frequently observed in the aforementioned populations despite the immense amount of physiologic serine protease inhibitors (serpins) because none of them can efficiently inhibit FXIa, 48 thus allowing 80% to 90% of FXIa to survive in blood for at least 30 minutes during citrate plasma preparation. 13 From the four designated cohorts based on injury severity and/or shock, we found that, although the frequency was relatively consistent across all cohorts, the highest concentrations of FXIa occurred in the cohorts with shock and was seemingly independent of injury extent. We also observed a correlation between the concentrations of FXIa and FIXa (R 2 = 0.36) throughout the entire cohort of this study, whereas no correlations between the concentrations of TF and FXIa or FIXa were observed. These data suggest that the contact pathway is primarily responsible for FXIa generation in trauma patient blood, although the contribution from the TF-driven extrinsic pathway cannot be dismissed as TF is a membrane protein and plasma levels may not represent those in vivo. Our preliminary data (not shown) support this hypothesis and are consistent with previously published observations. 49 Although we are suggesting a pathway of FXIa generation driven by shock and independent of the TF-driven pathway, the mechanism of shock-triggered activation of the contact pathway remains unclear.
Downstream of FXI(a) is FIX(a), which can be activated by either FXIa of the contact pathway and/or the extrinsic tenase complex (FVIIa/TF) of the TF pathway. FIXa forms the intrinsic FXase complex with FVIIIa, which, in addition to the extrinsic FXase complex, activates FX and subsequently promotes thrombin generation. Published studies have showed that activation of FX by the intrinsic FXase complex as compared to that by the extrinsic FXase complex is approximately 50-fold more efficient, thus making FIXa a potential marker for hypercoagulability. Because of FIXa's incompletely formed active site in the absence of FVIIIa, inactivation of FXIa by plasma inhibitors is relatively inefficient, thus allowing FIXa to efficiently diffuse from TF-bearing cells to platelets and serve as a link between the initiation and propagation phases of coagulation. 12 Increased levels of FIXa have been observed in the prothrombotic states of acute coronary syndromes, 24 consistent with the prevalence observed in this study across all four cohorts. The absence of a clearly defined relationship or correspondence of FIXa to either injury severity and/or shock is consistent with a previous study that suggested the mechanism of regulating FIXa generation and longevity differs from those observed for TF and FXIa. 50 Limitations of this study include the following: (1) Analysis was limited to a single time-point (admission). It is likely that, given time and exacerbation, concentrations of TF, FXIa, and FIXa would alter. Additionally, complete data compilation and long-term follow-up would be necessary to evaluate predictive values of TF, FXIa, and FIXa levels in patients falling under the designated cohorts with and without blood product transfusions. (2) Analysis was limited to the quantitation of TF, FXIa, and FIXa and excluded any other related biomarkers that could prove informative to TIC. (3) The entire population size was quite small. This study was intended as an initial investigation of the effect of trauma and injury severity with or without shock on the concentrations of these three proteins as primary mediators of the contact and extrinsic coagulation cascades. Correlating the findings of a larger study to clinical outcomes could provide important prognostic information and a better understanding of the phenotype of coagulopathy induced by varying concentrations of these proteins and should be investigated next.
In conclusion, the current study demonstrates the presence of quantifiable TF and, for the first time reported in manuscript format, FXIa and FIXa activity in the majority of trauma patients. The frequency and concentration of TF is higher in patients with a higher trauma severity and is independent of shock, whereas FXIa is of the highest concentrations in patients with shock and does not seem to be significantly affected by trauma severity. FIXa correlates only slightly with both severe injury and the presence of shock. Taken together, these data suggest separate pathways of TF and FXIa generation based on injury severity and shock, respectively. This study is part of a larger work in progress, and we ultimately believe that measuring these three proteins could help in the stratification of trauma patients and, as a consequence, lead to an improved treatment. AUTHORSHIP S.M.P. analyzed plasma samples, participated in data analysis, and wrote the article. M.J.C. participated in the design of the study, recruited patients, and edited the article. A.S.C., M.F.N., L.Z.K., and B.M.H. took care of the patients, collected plasma samples, provided clinical data, and edited the article. S.B. designed the study, participated in data analysis, and edited the article.
